Tumor-informed MRD for Non-small Cell Lung Cancer

Inclusion Criteria: 1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); 2. Newly diagnosed patients who are planned to undergo surgical treatment; 3. Age ≥18 years, regardless of sex; 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1; 5. Written informed consent must be obtained prior to any study-related procedures, sampling, or analyses; patients must be able to provide sufficient tissue and/or blood samples required for the study, with tumor cell content ≥20% as confirmed by pathological assessment; 6. Ability to comply with study requirements, including assessment of treatment efficacy, adverse events, and prognosis; 7. Willingness to undergo next-generation sequencing (NGS) testing. Exclusion Criteria: 1. Patients unwilling to provide tissue and blood samples for genetic testing; 2. Patients who are mentally or medically unstable, rendering them unable or unwilling to provide written informed consent; 3. Patients deemed by the investigator to be unsuitable for participation in the study, or those with poor compliance with study procedures, restrictions, and requirements.